BALPHARMA · Bal Pharma Ltd · Biotechnology & Drugs
BALPHARMA · Bal Pharma Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
34.6% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹89 Cr
Revenue YoY
PAT YoY
+433.3%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
2.6
P/S (TTM)
0.5
Sector P/E
36.3
Dividend yield
+1.1%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| BALPHARMA (this stock) | 17.5 | 2.6 | +2.1% | +8.8% | 1.94 | +1.1% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
stable
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| BALPHARMA | 2026-07-21 | 16325 | 1 | STRONG | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedBal Pharma Limited reported a 23.07% YoY increase in PBT to INR 120.56 Mn in FY2022, with PAT at INR 85.74 Mn. The company received PLI approvals under MSME 'Category C' for API and intermediates, expecting revenue incentives over six years. However, its subsidiary Golden Drugs Pvt Ltd has incurred losses and negative net worth, with the company seeking merger approval from NCLT. The company faces outstanding tax dues and disputes, including GST and service tax liabilities, with some cases remanded for reassessment. Additionally, there are contingent liabilities from subsidiaries Lifezen Healthcare and Balace Clinic LLP, with recoverability amounts of INR 819.32 lakhs and INR 149.30 lakhs respectively, though management believes these can be recovered through new funding and marketing strategies.
- PBT increased by 23.07% YoY to INR 120.56 Mn in FY2022; PAT was INR 85.74 Mn.
- Received PLI approvals under MSME 'Category C' for API and intermediates, expecting revenue incentives over six years.
- Subsidiary Golden Drugs Pvt Ltd has incurred losses and negative net worth; merger application filed with NCLT.
- Outstanding tax dues and disputes, including GST and service tax liabilities, with some cases remanded for reassessment.
- Contingent liabilities from subsidiaries Lifezen Healthcare and Balace Clinic LLP amounting to INR 819.32 lakhs and INR 149.30 lakhs, respectively, with management expecting recovery through new funding and marketing strategies.
Key takeaway: Bal Pharma Limited reported improved profitability with a PLI scheme benefit but faces significant tax disputes and contingent liabilities from underperforming subsidiaries, which may impact future financial stability.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (1 item); Default / Covenant Breach (5 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
1 occurrenceRecent (last 12 months)
The company acknowledged non-compliance with SEBI (LODR) Regulations 17(1), 18(1), and 19(1)/19(2) for 43 days related to board composition and 3 days for the Statutory Committee. The non-compliance resulted in fines imposed by BSE Limited and National Stock Exchange.
Default / Covenant Breach
5 occurrencesRecent (last 12 months)
The company has delays in repayment of loans as of March 31, 2025, though no defaults are reported as of the balance sheet date.
Earlier (1-3 years ago)
The company has not defaulted in repayment of loans or other borrowing to its lender, except for the dues listed under various statutes such as Income Tax Act, 1961, Goods & Service Tax, and Service Tax, with specific amounts, periods, and pending forums mentioned.
The company has discrepancies between the balance as per schedule and balance as per books for certain loans, indicating potential defaults or covenant breaches.
Older (3+ years ago)
The company had delays in repayment of vehicle loans from Canara Bank Limited and HDFC Bank Limited for the month of July 2021 by four days and twelve days respectively.
The company has not defaulted in repayment of loans or other borrowing to its lenders, except for the cases mentioned, where revised repayment schedules have been requested from banks.
Routine disclosures
Contingent Liability
5 occurrencesRecent (last 12 months)
The company has received show cause notices under Central Excise and Service Tax laws for the years 2007-08 onwards, with assessments in progress as of 31 March 2026, and no assessment orders have been received yet.
Earlier (1-3 years ago)
The company has received show cause notices under Central Excise and Service Tax laws for the years 2007-08 onwards, with assessments in progress as of 31 March 2024. The assessment orders have not been received yet.
Bal Pharma Limited has received show cause notices under Central Excise and Service Tax laws for the years 2007-08 onwards. The assessments are in progress, and the company has not received the assessment orders yet. In some cases, appeals have been remanded back for reassessment.
Older (3+ years ago)
Golden Drugs Private Limited's subsidiary has incurred losses and has negative net worth, and the company has filed for merger of the entity. The agreement for the same doesn't subsist and the loan is repayable on demand.
Bal Pharma Limited has received modified assessment orders under tax laws with a demand of Rs 5.84 lakhs, including interest of Rs 3.87 lakhs, and is awaiting approval under the Kerala Amnesty scheme 2021 for a waiver of 100% interest and 40% tax demand.
Related-Party Transaction
5 occurrencesRecent (last 12 months)
The company has disclosed related-party transactions involving Micro Labs Limited, Desa Marketing International, Siroya Construction, Siroya Wellness, Siroya Properties & Holdings, Siroya Developers, and Key Management Personnel such as Shailesh D. Siroya, Himesh Virupakshaya, Bharath Bhushan D. V., and others.
Earlier (1-3 years ago)
The company received a notice from NSE on 28 June 2024 for a 1-day delay in filing related party transactions disclosure and paid the penalty.
The company has disclosed related party transactions with entities such as Golden Drugs Private Limited, Lifezen Healthcare Private Limited, and individuals like Shailesh D Siroya, involving subcontracting expenses, commissions, rental expenses, and loans given.
Older (3+ years ago)
The company is seeking shareholder approval to renew a 3-year contract with Desa Marketing International, a related party owned by Mr. Shailesh Siroya, the Managing Director, as required under SEBI regulations and the Companies Act.
The company has related-party transactions with entities including Golden Drugs Private Limited, Balance Clinics LLP, Bal Research Foundation, Lifezen Healthcare Private Limited, Desa Marketing International, Siroya Construction, and Siroya Wellness, which are owned or controlled by the Managing Director or his relatives.
Management & Board Governance
1 occurrenceRecent (last 12 months)
C. D. Kotian - Whole-time Director resigned on May 16, 2025.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
0.91% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).